Atossa Therapeutics, Inc.
ATOS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001488039
No open-market purchases or sales by Atossa Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $2.60M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Atossa Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 59 | 51 | −8 |
| Shares | 19.0M | 17.9M | −1.08M (−5.7%) |
| Value | $15.8M | $9.49M | −$6.36M (−40.1%) |
New holders (6)
Institutions that held Atossa Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bank of Montreal | 175,699 | $105.2K | 0.00% |
| Susquehanna International Group, LLP | 96,490 | $51.0K | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 17,967 | $9.50K | 0.00% |
| Cetera Advisor Networks LLC | 10,432 | $5.51K | 0.00% |
| Rockefeller Capital Management L.P. | 5,000 | $2.00K | 0.00% |
| Belvedere Trading LLC | 501 | $265 | 0.00% |
Sold out (14)
Institutions that held Atossa Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Ergoteles LLC | 316,253 | $264.0K |
| Qube Research & Technologies Ltd | 91,680 | $76.0K |
| Gsa Capital Partners LLP | 71,901 | $60.0K |
| LMR Partners LLP | 41,730 | $35.0K |
| Price T Rowe Associates Inc | 34,400 | $29.0K |
| Susquehanna Fundamental Investments, LLC | 34,788 | $29.0K |
| Principal Financial Group Inc | 14,642 | $12.0K |
| Ameriprise Financial Inc | 11,007 | $9.00K |
| Private Advisor Group, LLC | 10,013 | $8.00K |
| Federated Hermes, Inc. | 668 | $1.00K |
| Abound Wealth Management | 6 | $5 |
| The PNC Financial Services Group, Inc. | 6 | $0 |
| UBS Group AG | 359 | $0 |
| Bogart Wealth, LLC | 500 | $0 |